Cross-protective Efficacy of NA-based mRNA Influenza Vaccine Candidates

707 post-2009 A(H1N1)pdm09 NA sequences were analyzed computationally to design two mRNA vaccine constructs. Mice immunized with NA-D1 or NA-E2 constructs were challenged with homologous H1N1 or heterologous H5N1 viruses. The data likely contains results on antibody titers and protection efficacy, supporting NA as a complementary antigen for broader influenza vaccines.

Use Cases

• Analyze NA sequence conservation patterns based on the 707 analyzed sequences
• Evaluate homologous vaccine protection efficacy based on the mouse challenge results
• Assess heterologous cross-protection potential based on the partial H5N1 challenge results
• Compare computationally designed vaccine constructs based on the NA-D1 and NA-E2 designs

Strengths

• Analysis based on 707 specific influenza NA sequences
• Includes results from both homologous (H1N1) and heterologous (H5N1) challenge experiments

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download

Provenance

Source

figshare

Collection Method

Computational analysis of viral sequences followed by experimental mouse challenge studies.

Freshness

Last updated 2026-04-09 05:14:53; freshness should be verified